Skip to main content
Signal8

Q/C TECHNOLOGIES, INC. (QCLS) Form 8-K — Nov 20, 2026

$QCLSForm 8-KItems 1.01, 3.03, 9.01Filed Nov 20, 2026, 5:20 PM ET0001493152-26-053558Original filing

On November 20, 2026, Q/C Technologies entered into an Omnibus Amendment Agreement with PharmaCyte Biotech, Inc., which holds at least a majority of both the Series G and Series H convertible preferred stock and thereby constitutes the Required Holders under each certificate of designations. The agreement amended both certificates of designations and the Series G Long-Term Warrants, raising PharmaCyte's beneficial ownership limitation on conversions and warrant exercises to 49.99% of outstanding common stock, versus 4.99% for other holders. Amendments became effective upon filing with the Delaware Secretary of State on November 20, 2026.

Key figures

Series h maturity new
2027-09-02
Series h maturity old
2027-03-02
Series g authorized shares
12826273
Series h authorized shares
7000
Pharmacyte beneficial ownership cap
49.99%
Series g long term warrant term years
5
Other holders beneficial ownership cap
4.99%
Series g short term warrant term months
18

AI analysis

Red flags4 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    Q/C TECHNOLOGIES, INC. (QCLS) Form 8-K — Nov 20, 2026: AI Analysis | Signal8